125 related articles for article (PubMed ID: 34558819)
1. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
[TBL] [Abstract][Full Text] [Related]
2. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
3. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
Sefrioui D; Verdier V; Savoye-Collet C; Beaussire L; Ghomadi S; Gangloff A; Goria O; Riachi G; Montialoux H; Schwarz L; Tuech JJ; Frebourg T; Michel P; Sarafan-Vasseur N; Di Fiore F
Int J Cancer; 2022 Feb; 150(3):532-541. PubMed ID: 34622951
[TBL] [Abstract][Full Text] [Related]
4. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
[TBL] [Abstract][Full Text] [Related]
5. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Li Z; Xiao D; Li X; Zhan P; Wang J; Zhang H
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):885-892. PubMed ID: 30807446
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
7. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
8. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Park S; Lee EJ; Rim CH; Seong J
Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
[TBL] [Abstract][Full Text] [Related]
9. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
10. The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
Pan J; Zhang YF; Yang HY; Xu HF; Lu X; Sang XT; Zhong SX; Mao YL
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):406-12. PubMed ID: 26256086
[TBL] [Abstract][Full Text] [Related]
11. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
El-Mazny A; Sayed M; Sharaf S
Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
[TBL] [Abstract][Full Text] [Related]
12. Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.
Dong X; Chen G; Huang X; Li Z; Peng F; Chen H; Zhou Y; He L; Qiu L; Cai Z; Liu J; Liu X
Mol Oncol; 2022 May; 16(10):1986-1999. PubMed ID: 34939323
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
[TBL] [Abstract][Full Text] [Related]
17. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
[TBL] [Abstract][Full Text] [Related]
19. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
20. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
Front Immunol; 2021; 12():754961. PubMed ID: 34691076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
